journal
MENU ▼
Read by QxMD icon Read
search

Leukemia & Lymphoma

journal
https://www.readbyqxmd.com/read/30234409/oxidative-stress-in-chronic-lymphocytic-leukemia-still-a-matter-of-debate
#1
Giovanni D'Arena, Elisa Seneca, Ilaria Migliaccio, Vincenzo De Feo, Aldo Giudice, Francesco La Rocca, Mario Capunzo, Gioacchino Calapai, Agostino Festa, Michele Caraglia, Pellegrino Musto, Eugenio Luigi Iorio, Vitalba Ruggieri
There is a large body of evidence showing a strong correlation between carcinogenesis of several types of human tumors, including chronic lymphocytic leukemia (CLL), and oxidative stress (OS). The mechanisms by which OS may promote cancer pathogenesis have not been completely deciphered yet and, in CLL, as in other neoplasms, whether OS is a primary cause or simply a downstream effect of the disease is still an open question. It has been demonstrated that, in CLL, OS concomitantly results from increased reactive oxygen species (ROS) production, mainly ascribable to CLL cells mitochondrial activity, and impaired antioxidant defenses...
September 20, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30234407/treatment-patterns-health-care-resource-utilization-and-costs-in-patients-with-relapsed-refractory-hodgkin-lymphoma-treated-with-brentuximab-vedotin
#2
Changxia Shao, Jinan Liu, Wei Zhou, Monika K Raut, Matthew Monberg, Xiting Cao, Alejandro D Ricart, Arun Balakumaran
Data are limited on the real-world utilization and costs of brentuximab vedotin (BV) among patients with relapsed/refractory Hodgkin lymphoma (rrHL) in the United States. A total of 219 BV patients identified from the Truven MarketScan® databases were followed up for a median of 2.9 years before and 1.0 year after initiation of BV. Of these patients, 109 (50.6%) received systemic therapy after BV (post-BV ST). Median duration of treatment was short for BV (2.1 months) and post-BV ST treatment (1.3 months); time to next treatment was 6...
September 20, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30234406/frequent-and-reliable-engraftment-of-certain-adult-primary-acute-lymphoblastic-leukemias-in-mice
#3
Birgitta Christine Heckl, Michela Carlet, Binje Vick, Catrin Roolf, Ameera Alsadeq, Michaela Grunert, Wen-Hsin Liu, Andrea Liebl, Wolfgang Hiddemann, Rolf Marschalek, Denis Martin Schewe, Karsten Spiekermann, Christian Junghanss, Irmela Jeremias
No abstract text is available yet for this article.
September 20, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30234405/prognostic-impact-of-diagnosis-to-treatment-interval-dti-in-diffuse-large-b-cell-lymphoma-patients-a-real-life-monocentric-study
#4
Vincent Camus, Sydney Dubois, Fabrice Jardin, Hervé Tilly
No abstract text is available yet for this article.
September 20, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30234404/new-lessons-learned-in-t-pll-results-from-a-prospective-phase-ii-trial-with-fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab-induction-followed-by-alemtuzumab-maintenance
#5
Natali Pflug, Paula Cramer, Sandra Robrecht, Jasmin Bahlo, Anne Westermann, Anna-Maria Fink, Alexandra Schrader, Petra Mayer, Sebastian Oberbeck, Till Seiler, Thorsten Zenz, Jan Dürig, Karl-Anton Kreuzer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek, Marco Herling, Georg Hopfinger
Clinical trials in T-cell prolymphocytic leukemia (T-PLL) are scarce. Based on a precursor study testing fludarabine, mitoxantrone, and cyclophosphamide followed by alemtuzumab (FMC-A), we aimed to improve this regimen by upfront combining subcutaneous (s.c.) alemtuzumab with FMC for four cycles followed by an alemtuzumab-maintenance (FMCA + A). This prospective multicenter phase-II trial assessed response, survival, and toxicity of that regimen administered to pretreated (n = 4) and treatment-naïve (n = 12) T-PLL patients...
September 20, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30234403/consolidation-treatment-with-yttrium-90-ibritumomab-tiuxetan-after-new-induction-regimen-in-advanced-stage-follicular-lymphoma-update-results-from-the-spanish-lymphoma-oncology-group-trial-after-a-median-follow-up-of-8-5-years
#6
Mariano Provencio, Fernando Franco, José Gómez-Codina, Cristina Quero Blanco, Marta Llanos, Francisco Garcia-Arroyo, Luis de la Cruz, Josep Gumá, Juan Ramón Delgado, Ruth Álvarez, José Ignacio Chacón, Ana Royuela, Antonio Rueda
No abstract text is available yet for this article.
September 20, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30234400/predictive-models-for-splenic-response-to-jak-inhibitor-therapy-in-patients-with-myelofibrosis
#7
Kamal Menghrajani, Philip S Boonstra, Jessica A Mercer, Cecelia Perkins, Krisstina L Gowin, Alissa A Weber, Ruben Mesa, Jason R Gotlib, Lixia Wang, Jack W Singer, Moshe Talpaz
JAK inhibitors for myelofibrosis (MF) reduce spleen size, control constitutional symptoms, and may improve survival. We studied the clinical characteristics of 548 MF patients treated with JAK inhibitors from 2008 to 2016 to better understand predictors of splenic response. Response was defined as a 50% decrease in spleen size at early (3-4 months on therapy) and late (5-12 months) timepoints after therapy initiation. Early response positively correlated with higher doses of JAK inhibitor, baseline spleen size 5-10 cm, and hemoglobin...
September 20, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30234399/management-of-primary-refractory-acute-myeloid-leukemia-in-the-era-of-targeted-therapies
#8
Christine M McMahon, Alexander E Perl
Primary refractory acute myeloid leukemia (AML), or primary induction failure, represents a continued challenge in clinical management. This review presents an overview of primary refractory disease and a discussion of risk factors for induction failure, including current evidence regarding the impact of karyotype and molecular mutation status on responsiveness to chemotherapy. We review the evidence for various treatment options for refractory AML including salvage chemotherapy regimens, allogeneic hematopoietic stem cell transplantation, targeted agents, and non-intensive therapies such as hypomethylating agents...
September 20, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30234387/efficacy-and-safety-of-rituximab-plus-bendamustine-for-gastric-marginal-zone-lymphoma
#9
Emanuele Cencini, Alberto Fabbri, Luana Schiattone, Monica Bocchia
No abstract text is available yet for this article.
September 20, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30227762/myelofibrosis-patients-can-develop-extramedullary-complications-including-renal-amyloidosis-and-sclerosing-hematopoietic-tumor-while-otherwise-meeting-traditional-measures-of-ruxolitinib-response
#10
Daria V Babushok, Ernest J Nelson, Jennifer J D Morrissette, Shivam Joshi, Matthew B Palmer, Dale Frank, Carolyn L Cambor, Elizabeth O Hexner
No abstract text is available yet for this article.
September 19, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30227761/carfilzomib-based-combination-regimens-are-highly-effective-frontline-therapies-for-multiple-myeloma-and-waldenstr%C3%A3-m-s-macroglobulinemia
#11
Maria Chaudhry, Raphael Steiner, Catherine Claussen, Krina Patel, Hans Lee, Donna Weber, Sheeba Thomas, Chun Feng, Behrang Amini, Robert Orlowski, Lei Feng, Elisabet E Manasanch
Multiple myeloma (MM) and Waldenström's macroglobulinemia (WM) are plasma cell disorders often treated with proteasome inhibitors. Recently, several studies evaluated carfilzomib as an initial treatment for these diseases and reported outstanding clinical outcomes. We conducted a retrospective study to report the efficacy and safety of frontline carfilzomib-based combinations in a standard of care setting. From 2014 until 2016 we identified newly diagnosed MM (n = 54) and WM (n = 6) patients treated with carfilzomib as initial therapy who met study inclusion criteria...
September 19, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30188240/comparison-of-clinical-features-and-survival-between-young-and-old-chronic-lymphocytic-leukemia-patients-a-single-center-study-from-turkey
#12
Rafet Eren, Abdulkadir Karişmaz, Damla Karataş, Mehmet Hilmi Doğu, Şermin Altindal, Osman Yokuş, Elif Suyani
We aimed to investigate whether the clinical characteristics, the rate of treatment demand and survival differ between chronic lymphocytic leukemia (CLL) patients <65 years (y) and ≥65 y. Sixty three (46%) patients were <65 y and 74 (54%) were ≥65 y. 28.6% (18/63) of the patients <65 required treatment, while this rate was 44.6% (33/74) for patients ≥65 y (p > .05). The probability of overall survival (OS) was 90 vs. 51% in patients <65 y and ≥65 y (p = .016). In univariate analysis, the age affected OS (p = ...
September 6, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30188238/bilateral-cystoid-macular-edema-in-a-patient-with-chronic-lymphocytic-leukemia-treated-with-ibrutinib
#13
Manuel Saenz-de-Viteri, Tomas Cudrnak
No abstract text is available yet for this article.
September 6, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30188237/can-rituximab-unlock-the-innate-potential-of-checkpoint-blockade-in-the-cns
#14
James L Rubenstein
No abstract text is available yet for this article.
September 6, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30188236/prognostic-impact-of-serum-soluble-interleukin-2-receptor-level-at-diagnosis-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-treated-with-r-chop
#15
Kento Umino, Shin-Ichiro Fujiwara, Daisuke Minakata, Chihiro Yamamoto, Akiko Meguro, Tomohiro Matsuyama, Kazuya Sato, Ken Ohmine, Tohru Izumi, Kazuo Muroi, Yoshinobu Kanda
Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous disease. To evaluate the clinical relevance of the serum soluble interleukin-2 receptor (sIL-2R) level, we retrospectively analyzed 178 patients aged ≥60 years who were newly diagnosed with DLBCL. We determined the cutoff value of the sIL-2R level to be 1280 U/mL using the area under the receiver operating characteristic curve. The high sIL-2R group exhibited significantly inferior 5-year progression-free survival (PFS) (36.2% vs. 86.1%, p < ...
September 6, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30188232/circulating-micrornas-expression-profile-in-newly-diagnosed-and-imatinib-treated-chronic-phase-chronic-myeloid-leukemia
#16
Letícia Antunes Muniz Ferreira, Juliana Capannacci, Newton Key Hokama, Célia Regina Nogueira, Michele Ceccarelli, Luigi Cerulo, Fulvio D'Angelo, Paula de Oliveira Montandon Hokama
Chronic myeloid leukemia (CML) is a stem cell derived malignant disorder result of translocation t(9;22)(q34;q11) called Philadelphia chromosome (Ph+ ). microRNAS (miRNAs) are involved in several biological processes, altering the progression of various pathologies, including CML. This study evaluated whether circulating miRNAs display differential expression profiles in peripheral blood of CML-Chronic Phase (CML-CP) patients newly diagnosed in comparison with CML-CP treated with imatinib. We obtained peripheral blood samples from CML-CP Ph+ patients divided among group 1 (untreated newly diagnosed) and group 2 (treated with imatinib)...
September 6, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30188230/il7r-overexpression-in-adult-acute-lymphoblastic-leukemia-is-associated-to-jak-stat-pathway-mutations-and-identifies-patients-who-could-benefit-from-targeted-therapies
#17
Valentina Gianfelici, Monica Messina, Francesca Paoloni, Nadia Peragine, Alessia Lauretti, Anna Lucia Fedullo, Filomena Di Giacomo, Marco Vignetti, Antonella Vitale, Anna Guarini, Sabina Chiaretti, Robin Foà
No abstract text is available yet for this article.
September 6, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30188229/the-risk-of-tuberculosis-in-cancer-patients-is-greatest-in-lymphoma-and-myelodysplastic-syndrome-myeloproliferative-neoplasm-a-large-population-based-cohort-study
#18
Chezi Ganzel, Barbara Silverman, Daniel Chemtob, Assaf Ben Shoham, Yonit Wiener-Well
Patients with cancer are at high risk for tuberculosis (TB). This study combined the Israeli databases of cancer and TB and examined the development of TB among all newly diagnosed cancer cases from 1993 to 2013. Patients were classified into groups according to their different malignancies. Among 495,335 cancer patients, 335 developed TB following cancer diagnosis. The cumulative incidence of TB following cancer diagnosis was highest among MDS/MPN (148.8/100,000 patients) and lymphoma (154.1/100,000 patients) (p = ...
September 6, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30188227/associations-between-the-peripheral-blood-wilms-tumor-gene-1-level-and-both-bone-marrow-blast-cells-and-the-prognosis-in-patients-with-myelodysplastic-syndrome
#19
Kiyomi Mashima, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Masahiro Ashizawa, Chihiro Yamamoto, Shinichiro Fujiwara, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
Wilms tumor gene 1 (WT1) is highly expressed in myelodysplastic syndrome (MDS) cells and is known to reflect the tumor burden in MDS. We evaluated the usefulness of WT1 mRNA levels for predicting the prognosis of MDS. At diagnosis, WT1 levels were strongly correlated with the percentage of blasts calculated based on non-erythroid cells, but not with that based on all nucleated cells (r = 0.57, p < .05 vs r = 0.42, p = .13). Among the allogeneic transplant recipients, the presence of two consecutive WT1 levels ≥100 copies/μg RNA with a median interval of one month was associated with a 77...
September 6, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30188226/cryptococcus-neoformans-infections-in-patients-with-lymphoproliferative-neoplasms
#20
Maria V Dioverti, Sameer A Parikh, Douglas R Osmon, Thomas M Habermann, Aaron J Tande
Cryptococcosis is a rare opportunistic infection increasingly associated with lymphoproliferative disorders. The clinical course and outcomes in these patients have not been extensively studied. We retrospectively reviewed charts of adult patients with lymphoproliferative disorders diagnosed with cryptococcal infections. A total of 34 patients were identified; 31 (91%) had a B-cell neoplasm and 3 (9%) had a T-cell neoplasm. The most frequent clinical syndrome was disseminated cryptococcal infection (38%), followed by pneumonia (29%)...
September 6, 2018: Leukemia & Lymphoma
journal
journal
30440
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"